Cumberland Pharmaceuticals Files 8-K on Financials
Ticker: CPIX · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1087294
Sentiment: neutral
Topics: financial-reporting, 8-K, financial-statements
Related Tickers: CPRX
TL;DR
CPRX dropped an 8-K on Nov 7th detailing financial results and exhibits.
AI Summary
Cumberland Pharmaceuticals Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing provides updates on the company's financial performance and related disclosures.
Why It Matters
This filing provides crucial updates on Cumberland Pharmaceuticals' financial health and operational results, which can impact investor decisions and market perception.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC. (company) — Registrant
- November 7, 2024 (date) — Date of Report
- Tennessee (location) — State of incorporation
- Nashville (location) — Principal Executive Offices City
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Cumberland Pharmaceuticals Inc.'s Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
On what date was this 8-K filed?
This 8-K was filed on November 7, 2024.
What is the state of incorporation for Cumberland Pharmaceuticals Inc.?
Cumberland Pharmaceuticals Inc. is incorporated in Tennessee.
What is the address of the principal executive offices?
The address of the principal executive offices is 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 62-1765329.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-11-07 17:09:54
Filing Documents
- cpix-20241107.htm (8-K) — 28KB
- a2024q3-ex991er.htm (EX-99.1) — 241KB
- cumberlandpharmaimageaa06a.jpg (GRAPHIC) — 37KB
- 0001628280-24-046399.txt ( ) — 466KB
- cpix-20241107.xsd (EX-101.SCH) — 2KB
- cpix-20241107_lab.xml (EX-101.LAB) — 21KB
- cpix-20241107_pre.xml (EX-101.PRE) — 12KB
- cpix-20241107_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 5, 2024, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release dated November 7, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: November 7, 2024 By: /s/ John Hamm John Hamm Chief Financial Officer